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Abstract During HLA class II synthesis in antigen-pre-
senting cells, the invariant chain (Ii) not only stabilizes
HLA class II complexes in the endoplasmic reticulum, but
also mediates their transport to specialized lysosomal
antigen-loading compartments termed MIICs. This study
explores an alternative HLA class II presentation pathway
in leukemic blasts that involves proteasome and transporter
associated with antigen processing (TAP)-dependent pep-
tide loading. Although HLA-DR did associate with Ii, Ii
silencing in the human class II-associated invariant chain
peptide (CLIP)-negative KG-1 myeloid leukemic cell line
did not affect total and plasma membrane expression levels
of HLA-DR, as determined by western blotting and flow
cytometry. Since HLA-DR expression does require peptide
binding, we examined the role of endogenous antigen-
processing machinery in HLA-DR presentation by CLIP-
leukemic blasts. The suppression of proteasome and TAP
function using various inhibitors resulted in decreased
HLA-DR levels in both CLIP- KG-1 and ME-1 blasts.
Simultaneous inhibition of TAP and Ii completely down-
modulated the expression of HLA-DR, demonstrating that
together these molecules form the key mediators of HLA
class II antigen presentation in leukemic blasts. By the use
of a proteasome- and TAP-dependent pathway for HLA
class II antigen presentation, CLIP- leukemic blasts might
be able to present a broad range of endogenous leukemia-
associated peptides via HLA class II to activate leukemia-
specific CD4? T cells.
Keywords MHC class II  Tumor cells  Antigen
presentation  Leukemia  Immune surveillance
Introduction
Professional antigen-presenting cells (APC), such as den-
dritic cells (DCs) and macrophages, can activate T cells
by efficiently processing antigens from both endogenous
and exogenous sources and presenting them at the plasma
membrane.
HLA class I antigen-processing machinery is essential
for the generation of endogenous peptides and loading onto
HLA class I molecules in the endoplasmic reticulum (ER).
One of its major components is the proteasome, a multi-
catalytic proteinase complex that specifically cleaves
ubiquitin-conjugated cytoplasmic proteins into small pep-
tides [1]. Another key player, the transporter associated
Electronic supplementary material The online version of this
article (doi:10.1007/s00262-010-0908-z) contains supplementary
material, which is available to authorized users.
M. M. van Luijn (&)  M. E. D. Chamuleau  A. Zevenbergen 
G. J. Ossenkoppele  A. A. van de Loosdrecht
Department of Hematology, Cancer Center Amsterdam,
VU Institute for Cancer and Immunology,
VU University Medical Center, De Boelelaan 1117,
1081 HV Amsterdam, The Netherlands
e-mail: m.luijn@vumc.nl
M. M. van Luijn  Y. Souwer  S. M. van Ham
Department of Immunopathology, Sanquin Research
and Landsteiner Laboratory, Academic Medical Center,
University of Amsterdam, Plesmanlaan 125,
1066 CX Amsterdam, The Netherlands
M. E. Ressing  E. J. Wiertz
Department of Medical Microbiology, University Medical
Center Utrecht, Utrecht and Leiden University Medical Center,
Leiden, The Netherlands
S. Ostrand-Rosenberg
Department of Biological Sciences, University of Maryland,
Baltimore County, Baltimore, MD, USA
123
Cancer Immunol Immunother (2010) 59:1825–1838
DOI 10.1007/s00262-010-0908-z
with antigen processing (TAP), mediates translocation of
these peptides into the ER [2], where further trimming to
nonameric peptides may be necessary for HLA class I
binding [3]. Upon complete folding in the ER lumen, the
class I/peptide complex is exported via the default secre-
tory pathway to the plasma membrane.
Exogenously derived peptides are generated in the
endosomal/lysosomal pathway and loaded onto HLA class
II molecules in specialized lysosomal antigen-loading
compartments, termed MIICs (or MHC class II-containing
compartments) [4, 5]. Newly synthesized HLA class II ab
heterodimers associate with the invariant chain (Ii or
CD74) in the ER lumen, which not only ensures stabil-
ization and proper folding, but also transport to the MIICs
[6, 7]. During transport to the MIICs, Ii is proteolytically
degraded, leaving a small fragment bound to the peptide-
binding groove [8]. In the MIICs, this class II-associated
invariant chain peptide (CLIP) is exchanged for an exog-
enous peptide by the peptide editor HLA-DM (DM) [9],
and the class II/peptide complex is transported to the
plasma membrane.
As extensively described in myeloid DCs, exogenous
peptides are able to interact with HLA class I molecules via
different processing pathways, a mechanism known as
cross-presentation [10, 11]. Endogenous peptides, on the
other hand, can be loaded onto HLA class II molecules as
well, although it remains controversial which processing
pathways underlie this type of peptide loading. In many
professional APCs, endogenous antigens are transferred to
the endosomal/lysosomal pathway for loading onto HLA
class II molecules [12]. Autophagy has been reported to
play a role in this process by delivering cytoplasmic
material for degradation in the lysosomes [13–15], but also
the proteasome could be involved by degrading cytoplas-
mic antigens before entering the endosomal/lysosmal
pathway [16, 17].
Although HLA class II transport into this pathway is
classically known to be dependent of Ii, the absence of Ii in
tumor APCs was shown to clearly increase HLA class II-
restricted presentation of endogenous peptides and their
capacity to activate tumor-specific CD4? T cells [18, 19].
Taking into account that the association of Ii with HLA
class II interferes with endogenous peptide binding in the
ER [20, 21], this suggests that in certain tumor APCs,
loading of HLA class II molecules with endogenous pep-
tides occurs via HLA class I antigen-processing machinery
instead of the endosomal/lysosomal pathway. It has
recently been shown that both the proteasome and TAP
were involved in the processing of HLA class II-restricted
viral epitopes [22], but less is known about this function of
HLA class I antigen-processing machinery in HLA class
II? tumor APCs. A better understanding of endogenous
antigen processing for HLA class II-restricted presentation
in HLA class II? tumor cells could be important for
developing approaches to optimize presentation of, yet
unidentified, tumor-associated antigens (TAAs), thereby
circumventing tumor immune escape.
We previously demonstrated that a low amount of
CLIP on HLA class II? leukemic blasts predicts an
improved clinical outcome for patients with acute myeloid
leukemia (AML) and enhances recognition by allogeneic
CD4? T cells [23]. In the current study, we show that an
Ii-independent, but proteasome- and TAP-dependent HLA
class II presentation pathway is active in a human CLIP-
myeloid leukemic cell line, which indicates that HLA
class I antigen-processing machinery mediates HLA class
II-restricted presentation of endogenous peptides in these
tumor cells.
Materials and methods
Cell lines and culturing
The human myeloid leukemic cell lines KG-1 and Kasumi-1
were obtained from the American Type Culture Collection
(ATTC) and frozen in aliquots at low cell passage. Culturing
of the KG-1 cell line was performed at 3 9 105 cells/ml in
IMDM (Gibco) supplemented with 20% FBS, 1% L-gluta-
mine (Gibco), 25 mM Hepes (Sigma-Aldrich, St Louis, MO,
USA) and 50 lM 2-ME (Gibco). The Kasumi-1 cell line
was maintained in RPMI 1640 medium (Gibco, Paisley,
UK) supplemented with 1% L-glutamine and 15% heat-
inactivated FBS (Greiner, Alphen a/d Rijn, The Netherlands)
with a cell density of 5 9 105 cells/ml. Cells were incubated
at 37C in a humidified atmosphere containing 5% CO2 and
the culture medium was refreshed every 3 days.
Antibodies and immunofluorescence staining
The following mouse monoclonal antibodies (MoAbs) were
used: PE-labeled anti-HLA-ABC (W6/32 clone; Dako,
Glostrup, Denmark) and IgG2a isotype control (BD, San
Jose, CA, USA); APC-labeled anti-HLA-DR (clone L243)
and IgG2a isotype control (BD); and 7-amino-actinomycin D
(7AAD; Via-Probe, BD). The PIN1.1 antibody (anti-Ii) was
kindly provided by Peter Cresswell (Howard Hughes
Medical Institute, Yale University School of Medicine, New
Haven, CT, USA) [24].
For immunofluorescence stainings, 1 9 105 cells were
pre-incubated with 10% human gamma-globulin (60 mg/ml;
Sanquin) for 10 min. Mouse MoAbs were added during
15 min for extracellular and 30 min for intracellular
staining. To analyze total protein expression, cells were
fixed with PBS 1% paraformaldehyde, permeabilized using
PBS 0.1% saponin (Sigma-Aldrich) and stained with the
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MoAb of interest. We examined the total amount of Ii by
staining with PIN1.1 followed by a second incubation step
of 20 min with rabbit anti-mouse (RAM) IgG conjugated to
PE (Dako). Stained cells were incubated at room tempera-
ture (RT), washed twice with PBS containing 0.1% HSA
and 0.05% sodium azide, and measured on a FACSAria
flow cytometer (BD). The same apparatus was used for flow
cytometric sorting of cells. Sorted cells were washed three
times with PBS before subsequent analysis or culture in
medium. We performed flow cytometric analyses by using
CellQuest software (BD) and determined extracellular
expression levels on viable (7AAD-) cells. Mean fluores-
cence intensity (MFI) was defined as the median value of all
gated cells relative to that of isotype control staining.
DNA constructs and retroviral vectors
Epstein-Barr virus (EBV)-encoded BNLF2a and bovine
herpes virus 1 (BHV-1)-encoded UL49.5 were amplified
from viral DNA with specifically selected primers and
PCR products were cloned into pLZRS-IRES-EGFP, as
previously reported [25, 26]. Information about this vector
can be obtained at http://www.stanford.edu/group/nolan/
retroviral_systems/retsys.html. Ii silencing was performed
using a pSIREN-RetroQ retroviral vector (Clontech) that
contains a specifically prepared Ii-siRNA insert (sequence
53) with a puromycin resistance gene [27].
Retroviral production, transductions and transfections
BNLF2a and UL49.5 retroviruses were produced using the
Phoenix amphotropic packaging system, as described at
http://www.stanford.edu/group/nolan/protocols/pro_helper_
dep.html. For the production of UL49.5 retroviruses, we
used a pLZRS vector that encodes a mutant form of
UL49.5, containing two alanines instead of lysines within
the cytoplasmic tail. This construct did not alter UL49.5-
mediated degradation and inhibition of the TAP complex
[28]. Retroviral transductions and transfections were
performed according to standard protocols [23]. The
possibility of off-target effects during these procedures
were excluded by using an irrelevant GFP-encoding ret-
rovirus (supplementary material, Fig. S2) and irrelevant
siRNAs [27].
For transfection experiments, 2 lg of pSIREN-RetroQ-
Ii-siRNA53 DNA was delivered into 2 9 106 cells using
the Amaxa nucleofection technology (Lonza, Basel,
Switzerland). The optimized protocol for the KG-1 cell
line is available at http://www.lonzabio.com. Before treated
cells were resuspended in culture medium again, we
first recovered them in IMDM (Gibco) without the addi-
tion of supplements for 30 min at 37C. Two days after
transfection, we added 1.0 lg/ml puromycin to select Ii-
siRNA53-transfected cells.
Co-immunoprecipitations and western blotting
To immunoprecipitate Ii proteins, 10 9 106 myeloid
leukemic blasts were washed three times with sterile PBS
(pH 7.4). Cell lysates were prepared by snap freezing the
samples in liquid nitrogen and incubating them upon
thawing for 45 min in 250 ll ice-cold lysis buffer, which
consisted of sterile PBS supplemented with 1% Ipegal and
15% protease inhibitor cocktail (Complete; 1 tablet/7.5 ml
H2O; Boehringer Mannheim Biochemica, Mannheim,
Germany). After removal of unlysed cell remnants and
nuclei by centrifugation in an Eppendorf micro-centrifuge
(5 min, 10,000 rpm), the protein content of the supernatant
was determined by the Bio-Rad protein assay (Biorad
Laboratories, Hercules, CA, USA). Then, 0.5 mg total cell
lysates were diluted in 0.5 ml ice-cold lysis buffer and
precleared with 1.0 lg of mouse IgG1 MoAb together with
20 ll Protein G PLUS-Agarose reagent (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) for 30 min. Ii was
immunoprecipitated using the PIN1.1 antibody and Protein
G PLUS-Agarose reagent (20 ll) in an overnight incuba-
tion. Ii immunoprecipitates were collected by centrifuga-
tion and washed four times with PBS before resuspending
in reducing electrophoresis sample buffer.
For western blotting, samples were electrophoresed on
12.5% polyacrylamide gels that contained SDS and trans-
ferred onto methanol-activated PVDF membranes. Differ-
ent protein amounts from total cell lysates were loaded on
gel: 10 lg for HLA-DRa, 20 lg for Ii and 70 lg for TAP1.
Mouse anti-DRa (clone 1B5 [29], 1:10,000), anti-Ii (clone
PIN1.1 [24], 1:1,000) and anti-TAP1 (clone 148.3 [30],
1:100) were used as primary MoAbs. To lower the staining
of interfering immunoprecipitated heavy and light chains,
mouse TrueblotTM ULTRA reagent (eBioscience, San
Diego, CA, USA) was added. Protein complexes were
visualized by Amersham ECL Western Blotting Detection
Reagents (GE Healthcare, Buckinghamshire, UK).
Proteasome inhibition assays
MG-132 and bortezomib (PS-341, Velcade) were kind gifts
from Dr. Gerrit Jansen (VU University Medical Center,
Amsterdam, The Netherlands). Each of these inhibitors was
added to 5 9 105 cells/ml culture medium per well in
increasing concentrations using six-well plates and cells were
incubated overnight at 37C in a humidified atmosphere
containing 5% CO2. Following incubation, cells were washed
twice with PBS containing 0.1% HSA and 0.05% sodium
azide and centrifuged for immunofluoresence staining.
Cancer Immunol Immunother (2010) 59:1825–1838 1827
123
Results
HLA-DR expression and transport to the plasma
membrane in CLIP- KG-1 blasts can occur
in the absence of the invariant chain
To study the Ii-dependency of HLA-DR expression by
CLIP- leukemic blasts, we silenced Ii expression in the
KG-1 myeloid leukemic cell line, which was found to lack
CLIP at the plasma membrane [23].
Western blot analysis demonstrated that Ii expression
was strongly inhibited in Ii-siRNA-treated KG-1 (KG-1/
Ii-siRNA) blasts (Fig. 1a). Interestingly, the total amount
of HLA-DR in KG-1/Ii-siRNA blasts was similar to that in
wild-type blasts. These results were confirmed by flow
cytometry, which showed that Ii was down-regulated for
[98% and, despite a very small population of HLA-
DR-Ii- blasts, total HLA-DR expression remained unaf-
fected in the vast majority of permeabilized, Ii-negative
KG-1/Ii-siRNA blasts (Fig. 1b, left panels).
Since the formation of HLA-DR molecules was not
impaired in KG-1/Ii-siRNA blasts, we next questioned
whether their transport to the plasma membrane was
disturbed by FACS analysis of HLA-DR expression on
intact cells (Fig. 1b, right panel). Again, no differences in
expression were encountered, implicating that the absence
of Ii does not interrupt HLA-DR transport to the plasma
membrane.
To assess if this Ii-independent HLA-DR expression
resulted from an inability of Ii to interact with HLA-DR
molecules, we immunoprecipitated Ii from KG-1 blasts and
determined its association with HLA-DR by western blot-
ting. As a positive control, the CLIP? Kasumi-1 myeloid
leukemic cell line was used, in which HLA-DR expression
did depend on the function of Ii [23]. Immunoprecipitation
of Ii from these cell lines revealed a similar association
with HLA-DR (Fig. 1c). Thus, the observed Ii-independent
HLA-DR expression in KG-1 blasts is not a reflection of
inefficient binding of Ii to HLA-DR.
These findings show that in CLIP- KG-1 blasts, HLA-
DR processing and transport to the plasma membrane
can occur independently of Ii expression, indicating the
involvement of other proteins in CLIP- leukemic blasts
that stabilize HLA class II molecules.
HLA-DR expression and transport to the plasma
membrane in CLIP- KG-1 blasts is dependent
on the function of the proteasome
Newly formed HLA-DR molecules are typically stabilized
by Ii (and later by CLIP) prior to peptide binding in the
MIICs [31, 32]. This raises the question of which alterna-
tive mechanism stabilizes these molecules in cells that do
not express Ii. We studied if Ii-independent HLA-DR
expression in KG-1 blasts may be accomplished by loading
of cytoplasmic peptides that are processed via HLA class I
antigen-processing machinery.
For classical loading of HLA class I molecules, cyto-
plasmic antigens need to be cleaved into small peptides by
the proteasome. To investigate the role the proteasome in
HLA-DR peptide loading, we blocked proteasomal activity
in KG-1 blasts by two inhibitors: MG-132, which inhibits
all catalytic b subunits, and bortezomib, which specifically
suppresses the b5 and, at higher concentrations, the b1
subunit of the 26S proteasome [33].
After incubation with each inhibitor, HLA class I
expression was decreased on the total KG-1 blast popula-
tion, as determined by flow cytometry (Fig. 2a), indicating
the effect of proteasome inhibition on endogenous peptide
loading. Interestingly, HLA-DR expression was strongly
down-regulated as well, in a dose-dependent manner
(supplementary material, Fig. S1a). In line with its broad
catalytic subunit specificity, MG-132 had a stronger effect
on both HLA class I and HLA-DR expression than bort-
ezomib (Fig. 2b). Similar effects of proteasome inhibition
were found for the myeloid leukemic cell line ME-1
(supplementary material, Fig. S1b). ME-1 blasts also lack
CLIP at the plasma membrane [23], indicating that our
findings reflect a general mechanism for leukemic blasts
that do not express CLIP.
As CLIP is abundantly expressed on Kasumi-1 blasts
[23], in contrast to the KG-1 and ME-1 myeloid leukemic
cell line, it is likely that cytoplasmic antigens in these
blasts are not processed for presentation by HLA-DR
molecules. Indeed, MG-132 and bortezomib did not reduce
plasma membrane expression of HLA-DR on Kasumi-1
blasts (Fig. 2c), while HLA class I expression was affected.
This demonstrates that HLA-DR expression on these blasts
does not involve proteasome activity and confirms that the
Fig. 1 Invariant chain involvement in HLA-DR expression by KG-1
blasts. a Protein extracts from Ii-siRNA-transduced KG-1 (KG-1/
Ii-siRNA) blasts were analyzed for Ii and total HLA-DR expression
by western blotting. Similar expression levels of b-tubulin verified
that both lanes were equally loaded with protein. Molecular weights:
Ii, 33 kD (p33); DRa, 34 kD; b-tubulin, 55 kD. b Ii versus total HLA-
DR expression levels for permeabilized KG-1 blasts (left panels), as
well as HLA-DR expression levels at the plasma membrane of intact,
7AAD- KG-1 blasts (right panel) after treatment with Ii-siRNAs, as
depicted in histograms (unfilled peaks) and dot plots. The filled
histograms represent isotype control stainings of the same cells. c Co-
immunoprecipitations of Ii with HLA-DR from protein extracts of
KG-1 and Kasumi-1 blasts. Ii immunoprecipitates were studied for
the association with HLA-DR by western blotting for DRa under
reducing conditions. Protein extracts of total lysates and IgG1
immunoprecipitates from the same blasts acted as positive and
negative controls, respectively, to confirm the specificity of the DRa
bands (34 kD) observed in the Ii immunoprecipitate-loaded lanes
c
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effect of both inhibitors in KG-1 and ME-1 blasts does not
result from aspecific protein down-regulation.
In conclusion, these data indicate that, in contrast to
CLIP? Kasumi-1 blasts, the transport of HLA-DR mole-
cules to the plasma membrane in at least a subpopulation of
KG-1 blasts and ME-1 blasts relied on proteasomal activ-
ity, which supports the notion that Ii-independent HLA-DR
expression in CLIP- leukemic blasts is related to loading
with cytoplasmic peptides.
HLA-DR expression and transport to the plasma
membrane in CLIP- KG-1 blasts is partly dependent
on the function of the TAP molecule
To further provide evidence that HLA class I antigen-
processing machinery is involved in cytoplasmic peptide
loading of HLA-DR molecules, we suppressed TAP-medi-
ated peptide processing in KG-1 blasts using two different
viral proteins: BNLF2a, which interferes with peptide and
ATP binding to TAP [25], and UL49.5, which prevents
conformational changes of TAP required for peptide trans-
location and targets TAP for proteasomal degradation [26].
After transduction with BNLF2a/GFP- and UL49.5/
GFP-encoding retrovirus, GFP? KG-1 blasts were flow
cytometrically sorted and analyzed for TAP expression by
western blotting (Fig. 3a). Although BNLF2a has been
described to only functionally suppress the TAP complex, a
lower amount of TAP1 was observed in BNLF2a-con-
taining KG-1 (KG-1/BNLF2a) blasts, as compared to wild-
type blasts. In UL49.5-containing KG-1 (KG-1/UL49.5)
blasts, TAP1 expression was completely down-regulated,
which agrees with the function of UL49.5 in targeting TAP
for proteasomal degradation. TAP2 expression was not
affected by these inhibitors, indicating that the inhibition of
TAP function was mediated by down-modulation of TAP1.
To test the impact of TAP inhibition on Ii-independent
HLA-DR expression, we analyzed the level of HLA-DR
expression on TAP-inhibited KG-1 blasts by flow cytom-
etry (Fig. 3b). HLA class I levels were determined as a
positive control for the function of TAP in classical
endogenous peptide loading. GFP? KG-1/BNLF2a and
KG-1/UL49.5 blasts not only showed decreased HLA class
I expression, but also a blast subpopulation with clearly
reduced HLA-DR levels (total down-regulation of 21 and
36%, respectively) at the plasma membrane. This effect
was the strongest in GFP? KG-1/UL49.5 blasts (53% of
GFP? blasts obtained a DR- phenotype), probably as the
cause of higher UL49.5 levels implicated by increased GFP
expression compared to KG-1/BNLF2a blasts (Fig. 3b) and
the complete degradation of TAP (Fig. 3a). In CLIP-
ME-1 blasts, TAP inhibition by using UL49.5 retrovirus
resulted in down-regulation of HLA-DR on the total blast
population (supplementary material, Fig. S3).
To investigate whether TAP is also involved in
Ii-dependent HLA-DR expression, CLIP? Kasumi-1 blasts
were transduced with UL49.5/GFP-encoding retrovirus as
well. After flow cytometric sorting and gating of GFP?
blasts, no differences were found in plasma membrane
expression of HLA-DR compared to wild-type blasts
(Fig. 3c). The strong reduction in TAP1 (Fig. 3a) and
HLA class I (Fig. 3c) expression showed that the func-
tion of TAP was indeed inhibited in Kasumi-1/UL49.5
blasts.
By different ways of TAP inhibition, we demonstrate
that in contrast to CLIP? Kasumi-1 blasts, HLA-DR
transport to the plasma membrane is dependent on the
function of TAP in a subpopulation of KG-1 blasts. This
suggests that Ii-independent HLA-DR expression in CLIP-
leukemic blasts results from loading with cytoplasmic
peptides processed by HLA class I antigen-processing
machinery.
Ii expression is inversely correlated to the
TAP-dependency of HLA-DR expression and transport
to the plasma membrane in CLIP- KG-1 blasts
Although HLA-DR expression was totally absent in a
subpopulation of TAP-inhibited KG-1 blasts, the other
subpopulation was still able to transport HLA-DR mole-
cules to the plasma membrane. To explain this difference
in effect, we flow cytometrically sorted the DR- (TAP-
dependent) and DR? (TAP-independent) subpopulation of
GFP? KG-1/UL49.5 blasts. Plasma membrane expression
of HLA class I was equally reduced on both subpopulations
compared to wild-type blasts, as determined by flow
cytometry (Fig. 4a). This indicated that UL49.5 protein
levels and the degree of TAP inhibition did not differ
between these subpopulations.
We next studied whether the differences in TAP depen-
dency of HLA-DR expression by KG-1 blasts involved the
function of Ii. Flow cytometric analysis revealed a close
association between total HLA-DR and Ii expression in
GFP? KG-1/BNLF2a and KG-1/UL49.5 blasts, as well
as in the DR-- and DR?-sorted subpopulations of GFP?
KG-1/UL49.5 blasts (Fig. 4b). During cell culture, both
HLA-DR and Ii expression were up-regulated again in the
Fig. 2 KG-1 (a, b) and Kasumi-1 (c) blasts treated with various
concentrations of MG-132 and bortezomib proteasome inhibitor were
analyzed for plasma membrane expression of HLA class I (‘ABC’)
and HLA-DR (unfilled histograms) together with their isotype
controls (filled histograms) by flow cytometry. To define the relative
MFI of HLA class I and HLA-DR expression levels, MFI values were
calculated for 7AAD- blasts at each concentration as described in
‘‘Materials and methods’’ and related to those of untreated blasts
(n = 3, ±SEM)
c
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Fig. 3 TAP inhibition in KG-1
and Kasumi-1 blasts and the
effect on HLA-DR expression.
a KG-1 and Kasumi-1 blasts
were transduced with retrovirus
encoding GFP together with
either BNLF2a or UL49.5
proteins, two different inhibitors
of TAP. After flow cytometric
sorting of GFP? blasts, TAP1
and TAP2 expression were
determined by western blotting.
All lanes were equally loaded
with protein, as b-actin was
expressed equally. Molecular
weights: TAP1, 71 kD; TAP2,
75 kD; b-actin, 42 kD.
b, c Flow cytometrically sorted
GFP? KG-1 (b) and Kasumi-1
(c) blasts containing either
UL49.5 or BNLF2a were
analyzed for GFP as well as
plasma membrane HLA class I
(‘ABC’) and HLA-DR
expression (unfilled histograms)
by flow cytometry. GFP and
plasma membrane HLA class I
levels were evaluated to assess
the transduction efficiency and
the degree of TAP inhibition,
respectively. The filled
histograms represent stainings
of the same cells with control
IgG
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DR--sorted subpopulation, while the DR?Ii? phenotype
remained stable in the DR?-sorted subpopulation of GFP?
KG-1/UL49.5 blasts (data not shown).
Thus, in one KG-1 blast subpopulation, TAP suppres-
sion accompanied an unexpected, transient decline in Ii
amount, probably resulting in the total absence of HLA-
DR. In another subpopulation of KG-1 blasts, the expres-
sion of Ii was not affected by TAP inhibition, which
indicated that HLA-DR expression in these blasts is res-
cued by association with Ii.
TAP and Ii together form the key mediators
of HLA-DR expression and transport to the plasma
membrane in CLIP- KG-1 blasts
To actually show the capacity of Ii in rescuing HLA-DR
expression in TAP-inhibited KG-1 blasts, we retrovirally
transfected the DR?-sorted subpopulation of GFP? KG-1/
UL49.5 (KG-1/UL49.5/DR?) blasts with Ii-siRNAs. In
agreement with the flow cytometric data (Fig. 4b), total
HLA-DR expression levels in GFP? KG-1/UL49.5/DR?
blasts were slightly increased in comparison to those
in wild-type blasts, as determined by western blotting
(Fig. 5a). This indicates that in the absence of TAP, the
association of HLA-DR molecules with Ii enhances their
stability. The total amount of HLA-DR strongly declined
after Ii silencing compared to non-silenced GFP? KG-1/
UL49.5/DR? and wild-type blasts. We confirmed these
results by flow cytometry (Fig. 5b; supplementary material,
Fig. S4), showing similar reduction in HLA-DR expression
after [90% Ii down-regulation in GFP? KG-1/UL49.5/
DR? blasts. This was contrary to the observations in KG-1/
Ii-siRNA blasts with the TAP complex still functional
(Fig. 1b).
Thus, TAP-independent HLA-DR expression and trans-
port to the plasma membrane in KG-1 blasts is confined to the
function of Ii, consistent with the classical pathway of HLA
class II antigen presentation.
Fig. 4 a DR- and DR? subpopulations emerging from UL49.5-
containing KG-1 blasts were flow cytometrically sorted and GFP?
blasts were examined for plasma membrane levels of HLA-DR and
HLA class I (‘ABC’) (unfilled histograms) with their isotope controls
(filled histograms) by flow cytometry. Analysis of HLA-DR expres-
sion confirmed the purity of flow cytometric sorting. b Total HLA-DR
expression was correlated to the expression of Ii in TAP-inhibited
KG-1 variants. Flow cytometric analysis was performed on perme-
abilized, GFP? KG-1 blasts that contained either BNLF2a or UL49.5
proteins. For GFP? KG-1/UL49.5 blasts, Ii expression was analyzed
in the flow cytometrically sorted DR- and DR? subpopulation as well
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To study if the function of TAP is also the determining
factor in Ii-independent HLA-DR expression, we trans-
duced KG-1/Ii-siRNA blasts with BNLF2a/GFP or
UL49.5/GFP retrovirus and flow cytometrically sorted
GFP? blasts. The inhibition of TAP resulted in a strong
down-regulation of total and plasma membrane expression
of HLA-DR in both GFP? KG-1/Ii-siRNA/BNLF2a and
KG-1/Ii-siRNA/UL49.5 blasts (Fig. 6). The difference in
effect of TAP inhibition on HLA-DR expression could be
explained by the higher transduction efficiency of UL49.5/
GFP compared to BNLF2a/GFP retrovirus (data not
shown), as noticed earlier in wild-type blasts (Fig. 3b).
In accordance with the requirement of Ii in TAP-inde-
pendent HLA-DR expression, the function of TAP is
critical for Ii-independent HLA-DR expression and trans-
port to the plasma membrane in KG-1 blasts. Overall,
simultaneous inhibition of TAP- and Ii-dependent antigen-
processing pathways in these blasts strongly down-
modulates HLA-DR expression, showing that TAP and Ii
together are the key regulators of HLA class II antigen
presentation.
Discussion
For an effective anti-tumor immune response, CTLs and
CD4? T cells need to be stimulated with TAAs presented
by tumor APCs [34]. Professional APCs present these
Fig. 5 Invariant chain silencing
in TAP-inhibited KG-1 blasts
and the effect on HLA-DR
expression. a The flow
cytometrically sorted DR?
subpopulation of GFP? KG-1/
UL49.5 blasts was treated with
Ii-siRNAs, and protein extracts
were analyzed for the amount of
TAP, Ii and HLA-DR by
western blotting. The amount of
b-tubulin in each lane confirmed
equal protein loading.
Molecular weights: TAP1, 74
kD; Ii, 33 kD (p33); DRa, 34
kD; b-tubulin, 55 kD. b Flow
cytometric analyses of Ii versus
total HLA-DR expression in
permeabilized, GFP? KG-1/
UL49.5/DR? blasts (left panel)
and the resulting HLA-DR
expression levels at the plasma
membrane of intact, 7AAD-
blasts (right panel; unfilled
histograms) after treatment with
and without Ii-siRNAs. The
filled histograms indicate the
corresponding isotype control
stainings
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peptides after recognition, engulfment and processing of
exogenously derived TAAs. Certain tumor cells, however,
can also serve as potent APCs by not only expressing
costimulatory molecules, but also presenting their own
peptides to T cells. Since impaired TAA presentation is a
known tumor escape mechanism [35], the components
involved in processing and presentation of endogenous
TAAs in tumor cells are interesting targets for immuno-
modulation. Previously, it has been reported that the CLIP-
KG-1 myeloid leukemic cell line is able to stimulate T cell
reactivity and presents HLA-DR molecules that are loaded
with peptides from endogenous rather than exogenous
sources [36, 37]. In this report, we show that in addition
to classical Ii-dependent HLA-DR antigen presentation,
KG-1 blasts use HLA class I antigen-processing machin-
ery, including the proteasome and TAP complex, to pro-
cess endogenous antigens for presentation via HLA-DR
molecules.
The Ii-independency of HLA-DR expression in KG-1
blasts (Fig. 1a, b) is not unique to this myeloid leukemic
cell line, as we recently found the same in the THP-1
myeloid leukemic cell line treated with Ii-siRNAs [23].
Although Ii plays an essential role in targeting HLA-DR
into the endosomal/lysosomal pathway [7], HLA-DR
molecules may also reach the MIICs in an Ii-independent
way, either indirectly via the plasma membrane or directly
by using the di-leucine endosomal sorting motif that
resides in the DRb-chain [38, 39]. In another myeloid
leukemic cell line, the Kasumi-1, however, we showed that
Ii silencing did affect plasma membrane expression of
HLA-DR [23], indicating that HLA-DR molecules in some
myeloid leukemic blasts cannot reach the MIICs without Ii.
These differences in Ii- (as well as TAP-) dependency of
HLA-DR expression might be explained by the low Ii/TAP
ratio in KG-1 blasts (Figs. 1a, 3a) as compared to Kasumi-1
blasts (Fig. 3a, data not shown).
Since at least a proportion of HLA-DR molecules were
immunoprecipitated along with Ii in KG-1 blasts (Fig. 1c),
it seems that both an Ii-dependent and Ii-independent
pathway were active. With regard to processing of endog-
enous antigens in these pathways, we showed that HLA-DR
expression levels at the KG-1 plasma membrane were
strongly influenced by proteasome inhibition (Fig. 2a, b).
This implies that in KG-1 blasts, proteasomal instead of
lysosomal degradation is involved in the generation of
cytoplasmic peptides for loading onto HLA class II mole-
cules. These findings differ from previous studies with
murine tumor cells, in which HLA class II antigen presen-
tation was dependent on the endosomal/lysosomal pathway
rather than the proteasome [40, 41].
After proteasomal processing of cytoplasmic antigens
in KG-1 blasts, the proteasome-generated peptides might
be transported to the MIICs for further trimming and
subsequent loading onto HLA-DR molecules via the
Ii-dependent pathway [12]. For HLA-DR molecules that
are processed in the Ii-independent pathway, however, the
intracellular site of peptide loading is still controversial. In
this report, we demonstrate that for a particular subpopu-
lation of KG-1 blasts, HLA-DR expression is dependent on
the function of TAP (Fig. 3b). Since HLA-DR expression
can occur in an Ii-independent way, it points to the ER as a
potential compartment where HLA-DR molecules are
Fig. 6 The impact of TAP
inhibition in Invariant Chain-
silenced KG-1 blasts on
HLA-DR expression. Ii-silenced
KG-1 blasts transduced with
BNLF2a/GFP or UL49.5/GFP
retrovirus were flow
cytometrically sorted for GFP?
blasts. Subsequently, we
determined Ii versus total HLA-
DR expression in permeabilized
GFP? blasts (left panel) and the
resulting expression levels of
HLA-DR on intact, 7AAD-
blasts (right panel; unfilled
histograms) by flow cytometry.
The filled histograms represent
stainings of the same cells with
control IgG
Cancer Immunol Immunother (2010) 59:1825–1838 1835
123
loaded with proteasome-generated and TAP-translocated
peptides.
The difference in TAP dependency of HLA-DR expres-
sion within the total KG-1 blast population might be
explained by a differential expression of specific HLA-DR
alleles with a high affinity for endogenous peptides. It
was reported that two allelic subtypes, DRB1*1101 and
DRB1*1401, on KG-1 blasts predominantly presented
endogenous peptides [36]. In addition, HLA-DR4 and -DR7
molecules have been shown to associate with endogenous
peptide presentation on tumor cells [42, 43]. Unexpectedly,
BNLF2a or UL49.5 proteins abrogated the expression of Ii in
the DR- KG-1 blast population (Fig. 4b), but were recov-
ered again during culture (data not shown). The suppression
of TAP might therefore transiently elicit additional effects
on the HLA class II-restricted presentation pathway in
this subset of blasts, as we found reductions in HLA-DM
expression levels as well (data not shown). This suggests
that the master regulator of the HLA class II presentation
pathway, CIITA, might be affected, which is currently under
investigation.
By simultaneous inhibition of Ii and TAP, we were able
to discriminate between the Ii-dependent and Ii-indepen-
dent HLA class II presentation pathway of endogenous
peptides in these tumor cells. We found that in the DR?
subpopulation of TAP-inhibited KG-1 blasts, only the Ii-
dependent pathway was functional, as Ii silencing strongly
reduced expression levels of HLA-DR (Fig. 5a). This
seems to be a threshold effect as the amount of HLA-DR
expressed is not directly proportional to the quantity of Ii
(Fig. 5b). In KG-1/Ii-siRNA blasts, HLA-DR expression
was clearly down-modulated after TAP suppression
(Fig. 6), showing that the Ii-independent pathway depends
on the function of TAP. The inability to express HLA-DR
molecules in the absence of both Ii and TAP function
agreed with the DR- phenotype found for the TAP-defi-
cient KG-1 subpopulation lacking Ii expression (Fig. 4b).
This study provides important insights into the intra-
cellular mechanisms of tumor cells to process endogenous
antigens for HLA class II-restricted presentation. Extensive
interplay between HLA class I and II presentation path-
ways was shown in blasts of the CLIP- KG-1 myeloid
leukemic cell line, which constitutively express HLA class
II molecules loaded with endogenous peptides. These
findings indicate that CLIP- leukemic blasts may be able
to present tumor-associated peptides on both HLA class I
and II molecules and underlines the hypothesis that abnor-
malities in the HLA class I antigen-processing machinery in
certain tumor cells may result in tumor escape from both
HLA class I- and HLA class II-restricted T cell recognition.
Besides their potential as antigen presenters, KG-1 blasts
can also be differentiated into functional DC-like cells
[37, 44], which makes these tumor cells ideal candidates for
the use as cellular vaccines. In general, the involvement of
endogenous antigen processing in HLA class II presentation
by tumor cells might introduce new immunomodulatory
approaches to simultaneously induce HLA class I and II
tumor antigen presentation.
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